A trial of two iron-dextran infusion regimens in chronic hemodialysis patients

Rajiv Agarwal, J. L. Davis, R. J. Hamburger

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: To test the ability to elicit a hemoglobin (Hb) response in patients on chronic hemodialysis, we prospectively compared two regimens of iron dextran administration, 100 mg once weekly (QW) or 100 mg once every dialysis (QD), both given for 10 doses. Patients and methods: Twenty-three consecutive patients on chronic hemodialysis received iron dextran intravenously if they had absolute or functional iron deficiency. There was no difference in the Hb response between regimens. Results: Both groups had a significant increase in Hb from 10.5 ± 1.5 g/dl at baseline, to 11.1 ± 1.7 g/dl at 1 month, 11.4 ± 2.1 g/dl at 2 months and 11.6 ± 1.9 g/dl at 3 months. The increment in Hb at 1 month was similar (QD 0.62 ± 1.245 g/dl vs. QW 0.64 ± 1.464 g/dl) between the two groups despite a large difference in the amount of iron received. Serum ferritin, transferrin saturations or epoetin dose did not change significantly. At the end of 3 months 12 patients did not need further iron therapy as judged by the serological markers of iron stores. Of these 12 patients, 3 had serum ferritins of > 1000 ng/ml. Weekly dosing of iron was associated with more medication errors than dosing every dialysis. Baseline iron stores could not predict the responsiveness to intravenous iron therapy as judged by an increase in Hb concentration at 1 month or at 3 months. Conclusion: This study confirms the efficacy of 1000 mg of intravenous iron administered over a 3-month period in patients with functional iron deficiency. It underscores the importance of careful monitoring of iron stores and highlights the need for developing better parameters of functional iron stores in hemodialysis patients.

Original languageEnglish
Pages (from-to)105-111
Number of pages7
JournalClinical Nephrology
Volume54
Issue number2
StatePublished - 2000

Fingerprint

Dextrans
Renal Dialysis
Iron
Hemoglobins
Ferritins
Dialysis
Medication Errors
Transferrin
Serum

Keywords

  • Anemia
  • Epoetin
  • Hemodialysis
  • Parenteral iron

ASJC Scopus subject areas

  • Nephrology

Cite this

A trial of two iron-dextran infusion regimens in chronic hemodialysis patients. / Agarwal, Rajiv; Davis, J. L.; Hamburger, R. J.

In: Clinical Nephrology, Vol. 54, No. 2, 2000, p. 105-111.

Research output: Contribution to journalArticle

Agarwal, Rajiv ; Davis, J. L. ; Hamburger, R. J. / A trial of two iron-dextran infusion regimens in chronic hemodialysis patients. In: Clinical Nephrology. 2000 ; Vol. 54, No. 2. pp. 105-111.
@article{2c8eb86649f7492ea36a69837e299f62,
title = "A trial of two iron-dextran infusion regimens in chronic hemodialysis patients",
abstract = "Aim: To test the ability to elicit a hemoglobin (Hb) response in patients on chronic hemodialysis, we prospectively compared two regimens of iron dextran administration, 100 mg once weekly (QW) or 100 mg once every dialysis (QD), both given for 10 doses. Patients and methods: Twenty-three consecutive patients on chronic hemodialysis received iron dextran intravenously if they had absolute or functional iron deficiency. There was no difference in the Hb response between regimens. Results: Both groups had a significant increase in Hb from 10.5 ± 1.5 g/dl at baseline, to 11.1 ± 1.7 g/dl at 1 month, 11.4 ± 2.1 g/dl at 2 months and 11.6 ± 1.9 g/dl at 3 months. The increment in Hb at 1 month was similar (QD 0.62 ± 1.245 g/dl vs. QW 0.64 ± 1.464 g/dl) between the two groups despite a large difference in the amount of iron received. Serum ferritin, transferrin saturations or epoetin dose did not change significantly. At the end of 3 months 12 patients did not need further iron therapy as judged by the serological markers of iron stores. Of these 12 patients, 3 had serum ferritins of > 1000 ng/ml. Weekly dosing of iron was associated with more medication errors than dosing every dialysis. Baseline iron stores could not predict the responsiveness to intravenous iron therapy as judged by an increase in Hb concentration at 1 month or at 3 months. Conclusion: This study confirms the efficacy of 1000 mg of intravenous iron administered over a 3-month period in patients with functional iron deficiency. It underscores the importance of careful monitoring of iron stores and highlights the need for developing better parameters of functional iron stores in hemodialysis patients.",
keywords = "Anemia, Epoetin, Hemodialysis, Parenteral iron",
author = "Rajiv Agarwal and Davis, {J. L.} and Hamburger, {R. J.}",
year = "2000",
language = "English",
volume = "54",
pages = "105--111",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

TY - JOUR

T1 - A trial of two iron-dextran infusion regimens in chronic hemodialysis patients

AU - Agarwal, Rajiv

AU - Davis, J. L.

AU - Hamburger, R. J.

PY - 2000

Y1 - 2000

N2 - Aim: To test the ability to elicit a hemoglobin (Hb) response in patients on chronic hemodialysis, we prospectively compared two regimens of iron dextran administration, 100 mg once weekly (QW) or 100 mg once every dialysis (QD), both given for 10 doses. Patients and methods: Twenty-three consecutive patients on chronic hemodialysis received iron dextran intravenously if they had absolute or functional iron deficiency. There was no difference in the Hb response between regimens. Results: Both groups had a significant increase in Hb from 10.5 ± 1.5 g/dl at baseline, to 11.1 ± 1.7 g/dl at 1 month, 11.4 ± 2.1 g/dl at 2 months and 11.6 ± 1.9 g/dl at 3 months. The increment in Hb at 1 month was similar (QD 0.62 ± 1.245 g/dl vs. QW 0.64 ± 1.464 g/dl) between the two groups despite a large difference in the amount of iron received. Serum ferritin, transferrin saturations or epoetin dose did not change significantly. At the end of 3 months 12 patients did not need further iron therapy as judged by the serological markers of iron stores. Of these 12 patients, 3 had serum ferritins of > 1000 ng/ml. Weekly dosing of iron was associated with more medication errors than dosing every dialysis. Baseline iron stores could not predict the responsiveness to intravenous iron therapy as judged by an increase in Hb concentration at 1 month or at 3 months. Conclusion: This study confirms the efficacy of 1000 mg of intravenous iron administered over a 3-month period in patients with functional iron deficiency. It underscores the importance of careful monitoring of iron stores and highlights the need for developing better parameters of functional iron stores in hemodialysis patients.

AB - Aim: To test the ability to elicit a hemoglobin (Hb) response in patients on chronic hemodialysis, we prospectively compared two regimens of iron dextran administration, 100 mg once weekly (QW) or 100 mg once every dialysis (QD), both given for 10 doses. Patients and methods: Twenty-three consecutive patients on chronic hemodialysis received iron dextran intravenously if they had absolute or functional iron deficiency. There was no difference in the Hb response between regimens. Results: Both groups had a significant increase in Hb from 10.5 ± 1.5 g/dl at baseline, to 11.1 ± 1.7 g/dl at 1 month, 11.4 ± 2.1 g/dl at 2 months and 11.6 ± 1.9 g/dl at 3 months. The increment in Hb at 1 month was similar (QD 0.62 ± 1.245 g/dl vs. QW 0.64 ± 1.464 g/dl) between the two groups despite a large difference in the amount of iron received. Serum ferritin, transferrin saturations or epoetin dose did not change significantly. At the end of 3 months 12 patients did not need further iron therapy as judged by the serological markers of iron stores. Of these 12 patients, 3 had serum ferritins of > 1000 ng/ml. Weekly dosing of iron was associated with more medication errors than dosing every dialysis. Baseline iron stores could not predict the responsiveness to intravenous iron therapy as judged by an increase in Hb concentration at 1 month or at 3 months. Conclusion: This study confirms the efficacy of 1000 mg of intravenous iron administered over a 3-month period in patients with functional iron deficiency. It underscores the importance of careful monitoring of iron stores and highlights the need for developing better parameters of functional iron stores in hemodialysis patients.

KW - Anemia

KW - Epoetin

KW - Hemodialysis

KW - Parenteral iron

UR - http://www.scopus.com/inward/record.url?scp=0033869987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033869987&partnerID=8YFLogxK

M3 - Article

C2 - 10968685

AN - SCOPUS:0033869987

VL - 54

SP - 105

EP - 111

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 2

ER -